# Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

> **NCT01188772** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 147 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** Sofosbuvir
- **DRUG:** Placebo to match sofosbuvir
- **DRUG:** PEG
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT01188772
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-04
- **Final completion:** 2012-05
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01188772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01188772, "Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01188772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*